|
1
|
Richardson HE, Stueland CS, Thomas J,
Russell P and Reed SI: Human cDNAs encoding homologs of the small
p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae
and Schizosaccharomyces pombe. Genes Dev. 4:1332–1344.
1990.
|
|
2
|
Wang JJ, Fang ZX, Ye HM, You P, Cai MJ,
Duan HB, Wang F and Zhang ZY: Clinical significance of
overexpressed cyclin-dependent kinase subunits 1 and 2 in
esophageal carcinoma. Dis Esophagus. 26:729–736. 2013.
|
|
3
|
Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM
and Wang F: Aberrant expression of Cks1 and Cks2 contributes to
prostate tumorigenesis by promoting proliferation and inhibiting
programmed cell death. Int J Cancer. 123:543–551. 2008.
|
|
4
|
Yu M, Zhong M and Qiao Z: Expression and
clinical significance of cyclin kinase subunit 2 in colorectal
cancer. Oncol Lett. 6:777–780. 2013.
|
|
5
|
Lee SW, Kang SB, Lee DS and Lee JU: Akt
and Cks1 are related with lymph node metastasis in gastric
adenocarcinoma. Hepatogastroenterology. 60:932–937. 2013.
|
|
6
|
Tanaka F, Matsuzaki S, Mimori K, Kita Y,
Inoue H and Mori M: Clinicopathological and biological significance
of CDC28 protein kinase regulatory subunit 2 overexpression in
human gastric cancer. Int J Oncol. 39:361–372. 2011.
|
|
7
|
Shen DY, Zhan YH, Wang QM, Rui G and Zhang
ZM: Oncogenic potential of cyclin kinase subunit-2 in
cholangiocarcinoma. Liver Int. 33:137–148. 2013.
|
|
8
|
Shen DY, Fang ZX, You P, Liu PG, Wang F,
Huang CL, Yao XB, Chen ZX and Zhang ZY: Clinical significance and
expression of cyclin kinase subunits 1 and 2 in hepatocellular
carcinoma. Liver Int. 30:119–125. 2010.
|
|
9
|
Li F, Zhao C and Wang L:
Molecular-targeted agents combination therapy for cancer:
Developments and potentials. Int J Cancer. 134:1257–1269. 2014.
|
|
10
|
Ricke J, Bulla K, Kolligs F,
Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, Schütte K,
Verslype C, Walecki J, et al: SORAMIC study group: Safety and
toxicity of radioembolization plus sorafenib in advanced
hepatocellular carcinoma: Analysis of the European multicentre
trial SORAMIC. Liver Int. 35:620–626. 2015.
|
|
11
|
Zhu AX, Duda DG, Ancukiewicz M, di Tomaso
E, Clark JW, Miksad R, Fuchs CS, Ryan DP and Jain RK: Exploratory
analysis of early toxicity of sunitinib in advanced hepatocellular
carcinoma patients: Kinetics and potential biomarker value. Clin
Cancer Res. 17:918–927. 2011.
|
|
12
|
Ganoth D, Bornstein G, Ko TK, Larsen B,
Tyers M, Pagano M and Hershko A: The cell-cycle regulatory protein
Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27.
Nat Cell Biol. 3:321–324. 2001.
|
|
13
|
Kita Y, Nishizono Y, Okumura H, Uchikado
Y, Sasaki K, Matsumoto M, Setoyama T, Tanoue K, Omoto I, Mori S, et
al: Clinical and biological impact of cyclin-dependent kinase
subunit 2 in esophageal squamous cell carcinoma. Oncol Rep.
31:1986–1992. 2014.
|
|
14
|
Franke TF, Kaplan DR and Cantley LC: PI3K:
Downstream AKTion blocks apoptosis. Cell. 88:435–437. 1997.
|
|
15
|
Burgering BM and Coffer PJ: Protein kinase
B (c-Akt) in phos-phatidylinositol-3-OH kinase signal transduction.
Nature. 376:599–602. 1995.
|
|
16
|
Franke TF, Yang SI, Chan TO, Datta K,
Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein
kinase encoded by the Akt proto-oncogene is a target of the
PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:727–736.
1995.
|
|
17
|
Hajduch E, Litherland GJ and Hundal HS:
Protein kinase B (PKB/Akt) - a key regulator of glucose transport?
FEBS Lett. 492:199–203. 2001.
|
